Increment

ICER (£/QALY)

Net benefit in £M

95 % credibility interval


Elderly and riskgroup → 2–4 y

2,613

74

(12–265.7)

2–4 y → 5–16 y

1,569

384.4

(85.4–1309.6)

5–16 y → 2–16 y

3,414

58.7

(8.4–212.8)

2–16 y → 2–16 y & 50–64 y

8,093

75.9

(–11.5 to 346.1)

2–16 y & 50–64 y → 2–64 y

8,868

198.8

(–46.8 to 950.8)

 Table of the incremental costeffectiveness ratios and net benefit for the proposed immunization strategies. Strategies are ordered in terms of their net cost, and the incremental costs and incremental benefits of the next most expensive strategy is compared with the previous one. Dominated strategies (50–64 year age group and 2–4 and 50–64 year age groups) have been excluded
 QALY, Qualityadjusted life year